GSK plc vs VanEck Semiconductor ETF — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while VanEck Semiconductor ETF trades at $568.66. The key difference: GSK plc pays a 3.49% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals.
| GSK | SMH | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $668.91 |
52-Week Low | $36.20 | $283.95 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SMH (VanEck Semiconductor ETF) trades at $574.81, down 4.19% amid a sector-wide selloff. Technical indicators show a bearish trend with resistance at $588 and support at $576. The ETF has gained 66.69% year-to-date but faces pressure from recent semiconductor weakness. News highlights SMH as a key AI infrastructure play with diversification benefits across chip designers and equipment makers.
Outlook remains tied to semiconductor cycle dynamics—AI demand supports long-term growth, but high valuations and crowded positioning pose near-term risks. Investors face volatility from memory price swings and geopolitical tensions, though SMH offers diversified exposure to the essential chip sector.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →